Table 1 Characteristics and fatigue measures of RA patients
From: The potential role of fatigue in difficult-to-treat rheumatoid arthritis
Variable | D2T RA (n = 38) | Non-D2T RA (n = 107) | p |
|---|---|---|---|
Age, mean (SD), years | 60 (13.02) | 56 (12.2) | 0.13 |
Female, n (%) | 24 (63.16) | 72 (67.29) | 0.69 |
Disease duration, median [p25-p75], years | 16 [ 11–21] | 13 [6–18] | 0.02 |
ESR, mean (SD) (mm/h) | 12.34(10.78) | 9.75 (9.25) | 0.22 |
CRP, mean (SD) (mg/dL)) | 0.47 (0.43) | 0.48 (0.71) | 0.79 |
RF positive, n (%) | 20 (58.82) | 69 (67.65) | 0.26 |
Positive Anti-CCP antibodies, n (%) | 21 (70) | 61 (67.78) | 0.75 |
DAS28, mean (SD) | 3.52 (1.08) | 2.47(1.06) | 0.01 |
Pain (VAS) mean (SD) | 53.55(26.96) | 30.42(24.03) | 0.01 |
HAQ, mean (SD) | 1.36 (0.63) | 0.71 (0.57) | 0.01 |
Comorbidities, n (%) | |||
Cardiovascular disease | 19 (63.3) | 52 (65.82) | 0.8 |
Depression | 5 (16.13) | 10 (12.5) | 0.59 |
Glucocorticoid use, n (%) | 26 (68.42) | 52 (48.60) | 0.03 |
Prednisone dose, median [p25-p75],mg (n = 126) | 5 [5-7.5] | 0 [0–5] | 0.01 |
Prednisone dose, intervals n(%) (n = 126) | |||
None | 12 (38.7) | 55 (57.9) | 0.01 |
1.25-2.5mg | 3 (9.7) | 8 (8.4) | |
5mg | 7 (22.6) | 27 (28.4) | |
>=7.5mg | 9 (29.0) | 5 (5.3) | |
Treatment | |||
Conventional DMARDs, n (%): | |||
None | 12 (11.22) | 2 (5.26) | 0.58 |
1 | 42 (39.25) | 15 (39.47) | |
2 or more | 53 (49.53) | 21 (55.27) | |
b/tsDMARDs, n (%): | |||
Anti TNF | 10 (26.32) | 69 (64.49) | 0.01 |
Non-Anti TNF | 19 (50) | 35 (32.71) | |
JAKi | 9 (23.68) | 3 (2.8) | |
Treatment ≥ 4 b/tsDMARDs, n (%) | 11 (28.95) | 5 (4.67) | 0.01 |